Loading clinical trials...
Loading clinical trials...
Imaging Quality and Potential Clinical Relevance of Phase Contrast
Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.
Category C2 Medicine product without CE label. Objective(s): Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography. Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography. Measurements and procedures: Phase 0: Phase contrast mammography of the mastectomy, tumorectomy or breast biopsy samples is performed after breast surgery in addition to the standard clinical procedures Phase 1: Phase contrast mammography is performed before the operation in case of known breast carcinoma in addition to the standard clinical procedures Phase 2: Phase contrast mammography is performed directly in the clinical routine. The result is compared with the result of the conventional digital mammography and the ultrasound examination. Number of Participants with Rationale: Phase 0: expected to be 30 Phase 1: expected to be 20 Phase 2: expected to be 300 (correct number will be defined according to Phase 1)
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Hospital Zurich - Diagnostic Radiology
Zurich, Canton of Zurich, Switzerland
University of Zurich
Zurich, Switzerland
Start Date
October 17, 2024
Primary Completion Date
September 1, 2029
Completion Date
September 1, 2030
Last Updated
February 5, 2025
350
ESTIMATED participants
Experimental Intervention
DIAGNOSTIC_TEST
Lead Sponsor
University of Zurich
Collaborators
NCT05673200
NCT05372640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions